Register and join us on February 22nd for a free NIH Technology Opportunity Webinar. Attendees will learn from the Eunice Kennedy Shriver National Institute of Child Health and Human Development’s (NICHD’s) inventors, Drs. Min S. Lee and Diana L. Blithe, about NICHD’s new injectable contraceptive formulation of levonorgestrel butanoate (LB). The new LB formulation allows for self-administration, eliminating the physician-administered injection requirement. Contrary to currently available injectable contraceptives, this new estrogen-free LB formulation also has minimal adverse side effects. It’s more stable, has a longer lasting concentrated dose and is reversible. Drs. Lee and Blithe will also discuss the results of NICHD’s completed Phase I Clinical Trial supporting the safety and effectiveness of this new LB formulation.

The NICHD seeks licensing and/or co-development partners for this technology.